NASDAQ$SCYX
Scynexis Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Scynexis reported its full year 2024 financial results, including a net loss and a decrease in revenue compared to the previous year, while also providing updates on its clinical programs and cash runway.
SCYNEXIS reported a net loss of $21.3 million for the full year ended December 31, 2024, with total revenue of $3.7 million, a significant decrease from $140.1 million in 2023. The company ended 2024 with $75.1 million in cash, cash equivalents, and investments, projecting a cash runway into Q3 2026.
- SCYNEXIS reported a full-year 2024 net loss of $21.3 million, or $0.44 basic loss per share.
- Total revenue for the full year 2024 was $3.7 million, primarily from license agreement revenue.
- Cash, cash equivalents, and investments totaled $75.1 million as of December 31, 2024, with a projected cash runway into Q3 2026.
- The Phase 1 trial of SCY-247 was initiated in December 2024, with results expected in Q3 2025, and progress is being made to restart the Phase 3 MARIO study in Q2 2025.
Headline financials
Revenue & EPS history
Scynexis · Revenue · Quarterly
$3.75M
Revenue by segment
Scynexis · $3.7M total across 1 segment · Q4 2024
- License Agreement Revenue$3.7M—100.0%
Forward guidance
SCYNEXIS anticipates key milestones in its clinical development programs and expects its current cash to fund operations into Q3 2026.
Tailwinds
- Expectation of cash runway into Q3 2026.
- Anticipated release of single and multiple ascending dose data from SCY-247 Phase 1 study in Q3 2025.
- Anticipated lifting of the clinical hold of the Phase 3 MARIO study in Q2 2025.
- SCY-247 has demonstrated highly encouraging preclinical results, highlighting its potential for clinical success.
- Progress towards restarting the MARIO trial for invasive candidiasis.
Headwinds
- Actual results may differ materially from forward-looking statements due to risks and uncertainties.
- Risks inherent in regulatory and other costs in developing products.
- Dependence on FDA's lifting of the clinical hold for the MARIO study restart.
- No specific revenue guidance provided for future periods.
- Continued net loss for the full year 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+12.3%
Avg return
Earnings day
+14.8%
Avg return
5 days after
+10.7%
Avg return
30 days after
53%
28 / 53 earnings
Positive
+619.7%
Q1 2026
Best reaction
-38.9%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +619.7% | +546.3% | +353.1% | |
| Q4 2025 | +2.9% | +16.1% | +14.6% | |
| Q3 2025 | -5.6% | -4.8% | +4.0% | |
| Q2 2025 | -5.3% | -6.5% | +32.5% | |
| Q1 2025 | +28.6% | +21.9% | -5.3% | |
| Q4 2024 | -1.0% | -5.9% | +1.0% | |
| Q3 2024 | +0.0% | -3.0% | -9.8% | |
| Q2 2024 | -5.4% | -7.0% | -31.7% | |
| Q1 2024 | +1.6% | +10.6% | +20.3% | |
| Q4 2023 | +4.2% | +1.8% | +8.1% | |
| Q3 2023 | +0.3% | -5.0% | -2.1% | |
| Q2 2023 | -8.0% | -1.7% | +13.0% | |
| Q1 2023 | -3.8% | +1.0% | -4.5% | |
| Q4 2022 | +24.8% | +21.1% | +7.1% | |
| Q3 2022 | -14.7% | -12.5% | -5.4% | |
| Q2 2022 | +0.7% | -4.5% | +2.1% | |
| Q1 2022 | +10.7% | +14.4% | +4.3% | |
| Q4 2021 | -14.5% | -17.7% | -45.1% | |
| Q3 2021 | -5.9% | +20.5% | +27.7% | |
| Q2 2021 | -2.2% | -6.2% | -5.8% | |
| Q1 2021 | +11.5% | +21.1% | +5.6% | |
| Q4 2020 | +1.0% | +8.2% | -2.0% | |
| Q3 2020 | +13.3% | +15.4% | +34.0% | |
| Q2 2020 | -2.0% | -2.9% | -28.0% | |
| Q1 2020 | -0.3% | -7.3% | +1.2% | |
| Q4 2019 | -22.7% | -29.7% | +1.0% | |
| Q3 2019 | +3.5% | -1.3% | -34.9% | |
| Q2 2019 | +2.8% | +0.0% | +2.8% | |
| Q1 2019 | -2.6% | -7.8% | -24.0% | |
| Q4 2018 | +19.0% | +37.3% | +45.2% | |
| Q3 2018 | -2.3% | -8.4% | -41.2% | |
| Q2 2018 | -6.1% | -10.1% | -12.2% | |
| Q1 2018 | +8.5% | +7.6% | +52.5% | |
| Q4 2017 | +2.7% | +3.4% | -11.0% | |
| Q3 2017 | -9.3% | -9.3% | +12.9% | |
| Q2 2017 | +1.9% | -2.5% | +35.6% | |
| Q1 2017 | -38.9% | -36.2% | -37.4% | |
| Q4 2016 | +9.0% | +11.9% | -5.2% | |
| Q3 2016 | +4.5% | +18.5% | +14.3% | |
| Q2 2016 | -1.9% | +3.8% | +41.8% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +6.9% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | -4.3% | — | — | |
| Q4 2014 | +5.1% | — | — | |
| Q3 2014 | -0.8% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2013 | +7.7% | — | — | |
| Q2 2014 | +7.7% | — | — | |
| Q1 2014 | +5.7% | — | — | |
| Q4 2013 | +5.7% | — | — | |
| Q1 2013 | +5.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro